<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR117">
 <label>117.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Le</surname>
    <given-names>RQ</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Yuan</surname>
    <given-names>W</given-names>
   </name>
   <name>
    <surname>Shord</surname>
    <given-names>SS</given-names>
   </name>
   <name>
    <surname>Nie</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Habtemariam</surname>
    <given-names>BA</given-names>
   </name>
   <name>
    <surname>Przepiorka</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Farrell</surname>
    <given-names>AT</given-names>
   </name>
   <name>
    <surname>Pazdur</surname>
    <given-names>R</given-names>
   </name>
  </person-group>
  <article-title>FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome</article-title>
  <source>Oncologist</source>
  <year>2018</year>
  <volume>23</volume>
  <issue>8</issue>
  <fpage>943</fpage>
  <?supplied-pmid 29622697?>
  <pub-id pub-id-type="pmid">29622697</pub-id>
 </element-citation>
</ref>
